|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL20 |
Gene summary for IL20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL20 | Gene ID | 50604 |
| Gene name | interleukin 20 | |
| Gene Alias | IL-20 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q9NYY1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 50604 | IL20 | P21T-E | Human | Esophagus | ESCC | 2.68e-21 | 1.20e+00 | 0.1617 |
| 50604 | IL20 | P52T-E | Human | Esophagus | ESCC | 2.52e-02 | 8.95e-02 | 0.1555 |
| 50604 | IL20 | P80T-E | Human | Esophagus | ESCC | 2.38e-02 | 6.47e-01 | 0.155 |
| 50604 | IL20 | P89T-E | Human | Esophagus | ESCC | 1.36e-08 | 1.15e+00 | 0.1752 |
| 50604 | IL20 | P107T-E | Human | Esophagus | ESCC | 4.88e-34 | 1.76e+00 | 0.171 |
| 50604 | IL20 | C04 | Human | Oral cavity | OSCC | 4.87e-29 | 1.96e+00 | 0.2633 |
| 50604 | IL20 | C51 | Human | Oral cavity | OSCC | 3.19e-03 | 5.31e-01 | 0.2674 |
| 50604 | IL20 | SYSMH2 | Human | Oral cavity | OSCC | 2.43e-05 | 3.86e-01 | 0.2326 |
| 50604 | IL20 | SYSMH3 | Human | Oral cavity | OSCC | 3.62e-03 | 2.35e-01 | 0.2442 |
| 50604 | IL20 | P1_cSCC | Human | Skin | cSCC | 6.38e-03 | 3.56e-01 | 0.0292 |
| 50604 | IL20 | P2_cSCC | Human | Skin | cSCC | 1.34e-03 | 2.69e-01 | -0.024 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000991324 | Skin | cSCC | epidermal cell differentiation | 78/4864 | 202/18723 | 5.12e-05 | 5.28e-04 | 78 |
| GO:000257324 | Skin | cSCC | myeloid leukocyte differentiation | 76/4864 | 208/18723 | 4.75e-04 | 3.60e-03 | 76 |
| GO:004568215 | Skin | cSCC | regulation of epidermis development | 28/4864 | 65/18723 | 2.02e-03 | 1.20e-02 | 28 |
| GO:190370626 | Skin | cSCC | regulation of hemopoiesis | 120/4864 | 367/18723 | 2.23e-03 | 1.32e-02 | 120 |
| GO:004561614 | Skin | cSCC | regulation of keratinocyte differentiation | 18/4864 | 37/18723 | 2.52e-03 | 1.43e-02 | 18 |
| GO:004563727 | Skin | cSCC | regulation of myeloid cell differentiation | 73/4864 | 210/18723 | 2.84e-03 | 1.59e-02 | 73 |
| GO:190210524 | Skin | cSCC | regulation of leukocyte differentiation | 92/4864 | 279/18723 | 5.20e-03 | 2.63e-02 | 92 |
| GO:000716224 | Skin | cSCC | negative regulation of cell adhesion | 98/4864 | 303/18723 | 7.45e-03 | 3.50e-02 | 98 |
| GO:004560414 | Skin | cSCC | regulation of epidermal cell differentiation | 24/4864 | 58/18723 | 7.50e-03 | 3.52e-02 | 24 |
| GO:004563919 | Skin | cSCC | positive regulation of myeloid cell differentiation | 38/4864 | 103/18723 | 9.38e-03 | 4.25e-02 | 38 |
| GO:000276123 | Skin | cSCC | regulation of myeloid leukocyte differentiation | 43/4864 | 120/18723 | 1.06e-02 | 4.66e-02 | 43 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| IL24 | IL20RA_IL20RB | IL24_IL20RA_IL20RB | IL10 | HNSCC | OSCC |
| IL24 | IL20RA_IL20RB | IL24_IL20RA_IL20RB | IL10 | HNSCC | Precancer |
| IL24 | IL22RA1_IL20RB | IL24_IL22RA1_IL20RB | IL10 | HNSCC | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL20 | SNV | Missense_Mutation | c.157G>A | p.Val53Met | p.V53M | Q9NYY1 | protein_coding | tolerated(0.07) | benign(0.132) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| IL20 | SNV | Missense_Mutation | c.408N>T | p.Glu136Asp | p.E136D | Q9NYY1 | protein_coding | deleterious(0.03) | possibly_damaging(0.6) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IL20 | SNV | Missense_Mutation | c.215N>G | p.Gln72Arg | p.Q72R | Q9NYY1 | protein_coding | tolerated(0.19) | benign(0.019) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IL20 | SNV | Missense_Mutation | c.41N>T | p.Ala14Val | p.A14V | Q9NYY1 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| IL20 | SNV | Missense_Mutation | c.408N>T | p.Glu136Asp | p.E136D | Q9NYY1 | protein_coding | deleterious(0.03) | possibly_damaging(0.6) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IL20 | SNV | Missense_Mutation | rs773706986 | c.236G>A | p.Arg79Gln | p.R79Q | Q9NYY1 | protein_coding | tolerated(0.31) | benign(0.034) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IL20 | SNV | Missense_Mutation | novel | c.137N>G | p.Phe46Cys | p.F46C | Q9NYY1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IL20 | SNV | Missense_Mutation | novel | c.332N>T | p.Ser111Ile | p.S111I | Q9NYY1 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IL20 | SNV | Missense_Mutation | novel | c.182N>G | p.Asp61Gly | p.D61G | Q9NYY1 | protein_coding | tolerated(0.08) | possibly_damaging(0.878) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IL20 | SNV | Missense_Mutation | c.519G>T | p.Glu173Asp | p.E173D | Q9NYY1 | protein_coding | tolerated(0.07) | possibly_damaging(0.5) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 50604 | IL20 | DRUGGABLE GENOME | NN-8226 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |